Kura Oncology, Inc. reported $77M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $77M (to Q2 2026). Net income: −$297M, trailing twelve months to Q2 2026. Free cash flow: −$117M, trailing twelve months to Q2 2026. Operating margin: −416%, trailing twelve months to Q2 2026.

KURAKura Oncology, Inc.

Healthcare

$10.51+11% 1Y

$10.51

$7.4052 weeks$13.59

KURA as reported

Kura Oncology, Inc. reported $77M of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.

$77M

Revenue, trailing twelve months · to Q2 2026 · every figure below is as filed, with no scoring applied

Net income: −$297M
Net income · +51% year on year · trailing twelve months to Q2 2026
Free cash flow: −$117M
Free cash flow · −196% year on year · trailing twelve months to Q2 2026
Operating margin: −416%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for KURA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$77M	n/a	Q2 2026
Net income	−$297M	+51%	Q2 2026
EPS	−$3.37	+49%	Q2 2026
Operating margin	−416%	n/a	Q2 2026
Net margin	−388%	n/a	Q2 2026
ROE	−284%	n/a	Q2 2026
ROA	−42%	n/a	Q2 2026
ROIC	56%	n/a	Q2 2026
Free cash flow	−$117M	−196%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.